Regulatory and clinical considerations for biosimilar oncology drugs

Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents—molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Bennett, Charles L, Chen, Brian, Hermanson, Terhi, Wyatt, Michael D, Schulz, Richard M, Georgantopoulos, Peter, Kessler, Samuel, Raisch, Dennis W, Qureshi, Zaina P, Lu, Z Kevin, Love, Bryan L, Noxon, Virginia, Bobolts, Laura, Armitage, Melissa, Bian, John, Ray, Paul, Ablin, Richard J, Hrushesky, William J, Macdougall, Iain C, Sartor, Oliver, Armitage, James O
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4404762/
https://ncbi.nlm.nih.gov/pubmed/25456378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70365-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados